Hepatitis B vaccination: how long does protection last? [Lancet. 1984] - PubMed

loading

Prophylaxis of viral hepatitis: transfusion transmitted disease and the hepatitis B vaccine. [Prog Clin Biol Res. 1983]
Prophylaxis of viral hepatitis: transfusion transmitted disease and the hepatitis B vaccine.
Holland PV. Prog Clin Biol Res. 1983; 143:357-67.
Response to hepatitis B virus vaccine in subjects with low levels of antibody to hepatitis B surface antigen. [N Engl J Med. 1984]
Response to hepatitis B virus vaccine in subjects with low levels of antibody to hepatitis B surface antigen.
Perrillo RP, Bodicky C, Campbell C, Sanders GE. N Engl J Med. 1984 May 31; 310(22):1463.
Hepatitis B surface antigen (HBsAg) subtype-specific antibodies in persons vaccinated against hepatitis B. [J Med Virol. 1984]
Hepatitis B surface antigen (HBsAg) subtype-specific antibodies in persons vaccinated against hepatitis B.
Jilg W, Delhoune C, Deinhardt F, Roumeliotou-Karayannis AJ, Papaevangelou GJ, Mushahwar IK, Overby LR. J Med Virol. 1984; 13(2):171-8.
Review [Active immunoprophylaxis of type B viral hepatitis]. [G Clin Med. 1984]
Review [Active immunoprophylaxis of type B viral hepatitis].
Spiga L, Mela GS. G Clin Med. 1984 May-Jun; 65(5-6):237-49.
Review [Hepatitis B virus infection: current developments]. [Ned Tijdschr Geneeskd. 1983]
Review [Hepatitis B virus infection: current developments].
van Ditzhuysen JM, van Loon AM, Yap SH. Ned Tijdschr Geneeskd. 1983 Nov 26; 127(48):2193-8.

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. [Hum Vaccin. 2011]
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Hum Vaccin. 2011 Sep; 7(9):958-65. Epub 2011 Sep 1.
Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. [Hum Vaccin. 2010]
Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults.
Beran J, Hobzova L, Wertzova V, Kuriyakose S, Leyssen M, Surquin M, Houard S. Hum Vaccin. 2010 Jul; 6(7):578-84. Epub 2010 Jul 1.
Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay. [Clin Diagn Lab Immunol. 2005]
Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay.
Wang CW, Wang LC, Chang MH, Ni YH, Chen HL, Hsu HY, Chen DS. Clin Diagn Lab Immunol. 2005 Dec; 12(12):1442-7.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Hepatitis B vaccination: how long does protection last?
Hepatitis B vaccination: how long does protection last?
Lancet. 1984 Aug 25 ;2(8400):458.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed